(Form-45) Import Permission issued from January 2009 to June 2010
| S.No. | Name of the firm | Date | Name of the molecule approved | Indication | dosage form and Strength |
| 1 | Taksal | 1/7/2009 | Tocilizumab | Rheumatoid Arthritis | 4, 10, 20 ml/vial |
| 2 | Sandor medicadis | 3/4/2009 | Fabrazyme (Agalsidase beta) | Treatment of long term enzyme therapy in patients with a confirmed diagnisis of Fabry disease (Alpha-galactosidase A deficiency) | 37.0mg/vial |
| 3 | Merck | 4/22/2009 | R-hu-INF beta-1a (Rebif) | treatment of relapsing multiple seleresis | 0.5ml pre-filled syringe |
| 4 | Baxter | 4/1/2009 | anti Haemophilic factor | ||
| 5 | Merck Specialiteis Pvt Ltd | 4/22/2009 | r-DNA Hu-Somatropin Hormone | Growth deficiency associated with proven insufficient secretion of endogenous growth hormone | 1.33mg/3.33mg |
| 6 | Merck Specilities | 4/1/2009 | Follitropin alfa (r-hu-FSH) | treatment of female infertility | 300IU/0.5ml, 450IU/0.75ml, 900IU/1.5ml |
| 7 | Merck Specilities | 4/22/2009 | Hu-somatropin hormone | Growth deficiency associated with proven insufficient secretion of endogenous growth hormoe | 1.33mg and 3.33mg |
| 8 | Merck Specilities | 4/1/2009 | r-hu-chorionic gonadotropin hormone (ovitrelle) | ||
| 9 | Claris | 5/29/2009 | GCSF | Increase neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | Each PFS contains 300mcg/0.9ml |
| 10 | Gufic lifesciences | 5/29/2009 | GCSF | Increase neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | Each PFS contains 300mcg/0.9ml |
| 11 | Eli Lilly | 5/20/2009 | Insulin lispro | diabeteic Mellitus | |
| 12 | Novo Nordisk | 5/14/2009 | Soluble Insulin Injection I.P. | for the treatment of patients with diabeteic Mellitus | each 3ml cartridges contains 100 IU/ ml |
| 13 | Novo Nordisk | 5/14/2009 | Biphasic Isophane Insulin Injection | for the treatment of patients with diabeteic Mellitus | each 3ml cartridges contains 100 IU/ ml |
| 14 | Novo Nordisk | 5/14/2009 | Isophane Insulin Injection | for the treatment of patients with diabeteic Mellitus | each 3ml cartridges contains 100 IU/ ml |
| 15 | Novo Nordisk | 5/14/2009 | Insulin Aspart | for the treatment of patients with diabeteic Mellitus | each 3ml cartridges contains 100 IU/ ml |
| 16 | Sandor Medicaids | 6/1/2009 | Cerezyme | Long-term enzyme replacement therapy in patients with non-neurological gaucher disease | 200, 400 units/vial |
| 17 | Chandra Bhagat pharma Ltd | 7/21/2009 | R-Hu-GCSF Injection | Increase of neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | Each PFS contains 300mcg/0.9ml |
| 18 | KSR phramacy | 7/10/2009 | GCSF | Increase neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | Each PFS contains 300mcg/0.9ml |
| 19 | VHB life sciences | 8/4/2009 | R-Hu-GCSF Injection | Increase oneutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | Each PFS contains 300mcg/0.9ml |
| 20 | USV Ltd | 9/2/2009 | R-Hu-GCSF Injection | Increase oneutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | 75mcg/0.30ml, 150mcgmcg/0.60ml & 300mcg/0.90ml |
| 21 | Trigenesis Life Sciences | 9/8/2009 | R-Hu-GCSF Injection | Increase neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | 75mcg/0.30ml, 150mcgmcg/0.60ml & 300mcg/0.90ml |
| 22 | Sanofi Synthelabo Ltd | 12/22/2009 | Rasburicase | Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure in patients with haematological malignancy with a tumor burden and at a risk of a rapid tumor lysis or shrinkage at initiation of chemotherapy | 1.5mg/ml, 7.5mg/ml powder and solvent for solution for infusion |
| 23 | Novo Nordisk India Pvt Ltd | 2/8/2010 | Liraglutide | Treatment of type-II Diabetes Mellitus | Each PFS contains 18mg/3ml |
| 24 | VHB Medisciences Ltd | 3/4/2010 | r-hu-GCSF-injection | Increase of neutrophilic count after bonemarrow transplantation, neutro-philic granulocytopenia reduced by chemotherpay of cancers inducing maligna-nt lymphoma, embryonic cell tumor, neuroblastoma. | 300mcg/0.9ml |
| 25 | Ferring Pharmaceuticals | 4/4/2010 | r-Hu-Growth Hormone (Somatropin) | Long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turner's syndrome | Each vial contains 4 mg (12 IU) |
| 26 | Sandor Medicaids Pvt Ltd | 5/13/2010 | Aldurazyme (Laronidase) | Patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS) and for Patients with Scheie form who have moderate to severe symptoms | Laronidase-----2.9 mg |
| 27 | Biogen Idec Biotech India Pvt Ltd | 5/28/2010 | Natalizumab | For the treatment of relapsing forms of Multiple Scheloris (MS) | Each vial of 15 ml contains: natalizumab--300mg |
| 28 | Bioviz technologies Pvt Ltd | 6/14/2010 | r-hu-GCSF-injection | For decreasing severity of chemotherapy induced neutropenia. Cancer patients receiving Myelosuppresice chemotherapy | Each PFS contains: r-Hu- GCSF-75mcg/0.3ml, 150mcg/0.6ml and 300mcg/0.9ml |
| 29 | Bioviz Technologies Pvt Ltd | 6/14/2010 | r-Hu-EPO | For the treatment of anemia due to chronic renal failure. | Each pre-filled syringe of 1ml contains: r-Hu-EPO-2,000 /4,000 IU |
| 30 | Scigen Biopharma Pvt Ltd | 6/18/2010 | R-Hu-Growth Hormone Injection | Long-term treatment of children who have growth failure associated due to endogenous growth hormone and for treatment of short stature in children with Turner's syndrome confirmed by chromosomal analysis | Powder for injection. Each vial after reconstitution contains 5.8 mg (17.41 IU); solution for injection. Each cartridge of 1.5ml contains 5mg (15 IU) and 10 mg (30 IU) |
| 31 | Bioviz Technologies Pvt Ltd | 6/14/2010 | r-hu-EPO (Bulk) |